Market open
Inhibrx Biosciences/$INBX
Inhibrx Biosciences shares are trading higher after the company reported its Q1 2025 financial results.
23 minutes ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inhibrx Biosciences
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Ticker
$INBX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
159
ISIN
US45720N1037
Website
INBX Metrics
BasicAdvanced
$157M
0.10
$112.62
-
-
Price and volume
Market cap
$157M
52-week high
$18.95
52-week low
$10.80
Average daily volume
127K
Financial strength
Current ratio
3.938
Quick ratio
3.747
Long term debt to equity
4.831
Total debt to equity
6.025
Interest coverage (TTM)
-19.52%
Management effectiveness
Return on assets (TTM)
-84.78%
Return on equity (TTM)
1,905.92%
Valuation
Price to earnings (TTM)
0.096
Price to revenue (TTM)
802.309
Price to book
1.17
Price to tangible book (TTM)
1.17
Price to free cash flow (TTM)
-0.814
Growth
Revenue change (TTM)
-88.89%
Earnings per share change (TTM)
-649.80%
What the Analysts think about INBX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Inhibrx Biosciences stock.
INBX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
INBX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Inhibrx Biosciences stock?
Inhibrx Biosciences (INBX) has a market cap of $157M as of May 15, 2025.
What is the P/E ratio for Inhibrx Biosciences stock?
The price to earnings (P/E) ratio for Inhibrx Biosciences (INBX) stock is 0.1 as of May 15, 2025.
Does Inhibrx Biosciences stock pay dividends?
No, Inhibrx Biosciences (INBX) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Inhibrx Biosciences dividend payment date?
Inhibrx Biosciences (INBX) stock does not pay dividends to its shareholders.
What is the beta indicator for Inhibrx Biosciences?
Inhibrx Biosciences (INBX) does not currently have a Beta indicator.